Predicting which pulmonary embolism patients will do well with oral anticoagulation and which will decompensate is a bit murky, at best. The treatment of pulmonary embolism (PE) has evolved quite a bit in just the past few years. Direct oral anticoagulants mean there is no longer a need to bridge patients to warfarin, and a push to treat more patients as outpatients followed. Peripheral, subsegmental PEs appear to pose little risk to a patient’s short-term morbidity and mortality, but what about segmental or submassive PEs?

Read More